Copolymer 1 (Cop 1) is a synthetic basic random copolymer of amino acids that has been shown to be effective in suppression of experimental allergic encephalomyelitis and is being tested as a 
tide p84-102 (an immunod nt epitope of BP) was also donstrated. Cop Myelin basic protein (BP) is a major autoantigen involved in the induction of experimental allergic encephalomyelitis (EAE), a cell-mediated autoimmune disease of the central nervous system (1) . EAE serves as an animal model for human demyelinating diseases including multiple sclerosis (MS) (2) . Although the myelin components that act as the autoantigen in MS have not been identified yet, recent studies suggest that T-cell reactivity to BP may be of significance in this disease (3) .
We have previously reported that suppression of EAE in various animal species may be induced by copolymer 1 (Cop 1), a synthetic basic random copolymer of amino acids (4) (5) (6) (7) (8) .
The immunological cross reactivity of Cop 1 with BP was conclusively established at the humoral level, using monoclonal antibodies to either BP or Cop 1 (9) , and at the cellular level (10) . Studies in mice suggest two possible mechanisms for Cop 1 activity in EAE. (i) Induction of antigen-specific suppressor cells: Cop 1 was found to induce suppressor T cells specific to BP that mediate prevention of clinical EAE (7, 11 (14) (15) (16) . The binding of peptides to MHC molecules on live target APCs has been demonstrated using iodinated peptides (17) or nonradioactive biotinylated peptides and fluorescently labeled avidin (16, 18) . Whereas both methods do not require the isolation of the individual MHC alleles, the use of biotinylated peptides to monitor their binding to the MHC is advantageous, since it measures only peptides bound to the surface MHC molecules on intact cells (14, 16, 19) . This approach can be utilized (20, 21) to demonstrate the binding not only of short peptides but also of larger molecules. Thus, by using biotinylated poly(L-Tyr,L-Glu)-poly(DL-Ala)--poly(L-Lys), a synthetic multichain polypeptide antigen of L-amino acids, and poly(D-Phe,D-Glu)-poly(D-Pro)--poly(DLys), a synthetic polymer composed of D-amino acids, this method was exploited to measure equilibrium and kinetics of binding to the MHC and the processing requirements (20, 21 (Bicester, England) . SJL/J and (BALB/c x SJL/J)F1 mice were obtained from The Jackson Laboratory. Mice were used at the age of 6-12 weeks.
Antigens. BP was isolated from spinal cords of human and mouse white matter as described (22 Blotinylation of the Antigens. Biotinylation of Cop 1, BP, and p84-102 was performed at 0C with biotin-N-hydroxysuccinimide (Sigma) as described (14) . Unreacted biotin was removed by dialysis. Analysis of the biotinylated derivatives (25) (Fig. 1 A-C) . Furthermore, APCs from naive and sensitized mice bound biotinylated Cop 1 to the same extent (87% vs. 83% in naive vs. sensitized mice, respectively).
We then tested the binding of Cop 1 to human APCs. No differences were observed when MNCs from a normal individual (90% cell staining) or a MS patient (91% cell staining) or the EBV-transformed B-cell line derived from this MS patient (87% cell staining) served as APCs. Consequently, EBV-transformed B-cell lines derived from eight MS patients of different HLA haplotypes were used to study the restriction of Cop 1 binding. As can be seen (Fig. 1 E-L Fig. 1P ). In addition, the binding of these antigens to L-EBV-B cells in the stationary phase, which led to limited expression ofHLA determinants, was low (29% compared to 90% of the regular Cop 1 binding, Fig. 10 ). On the other hand, poly(L-lysine), either preincubated with the APCs or coincubated with Cop 1 or BP, did not inhibit their binding to human APCs (data not shown). These results suggest that the binding of the biotinylated antigens is to MHC molecules and not to other cell surface molecules and that the interaction is specific and not due to the positive charge of the antigens.
The specificity of the binding of biotinylated Cop 1, BP, and p84-102 to the class II DR molecules on APCs of human origin was confirmed by its inhibition with anti-DR, but not with anti-DQ or anti-class I (ABC) antibodies (Table 1) .
Similarly, the binding to APCs of mouse orgin was inhibited by anti-I-A, but not by anti-H-2K or anti-H-2D, antibodies (Table 2 ). It should be noted that both anti-I-AS and anti-I-Ad completely inhibited the binding. The cause for this observation may be related to the existence of the class II molecules as heterodimers (27) EBV-transformed B-cell lines with these biotinylated antigens and with an excess of unbiotinylated antigens. molecules on APCs, we decided to examine whether these antigens compete for MHC binding. Thus, we incubated L-EBV-B cells with biotinylated Cop 1, BP, or p84-102 and unlabeled antigens for 20 hr at 37°C (Fig. 3 and Table 1 ). The results showed that the binding of BP was inhibited by Cop 1 and p84-102; however, Cop 1 inhibited the binding of BP at lower molar concentrations than p84-102 (Fig. 3A) . The binding of p84-102 was more efficiently inhibited by Cop 1 and BP than by p84-102 itself (Fig. 3B) . The binding of Cop 1 was inhibited by Cop 1, BP, and p84-102 at similar efficiencies. However, the level of inhibition by BP was somewhat lower than by Cop 1 or p84-102 (Fig. 3C) .
We next examined whether the blocking of HLA-DR determinants on the surface ofAPCs would lead to the inhibition of (Tables 1 and 2 ). (iii) This binding is characterized by its high efficiency (Fig. 1) and fast rates (Fig.  2) . Furthermore, Cop 1 competes with BP and its major epitope p84-102 for MHC binding (Fig. 3) displace bound BP. These observations provide a mechanism for the reported inhibition of murine and human T-cell responses to BP by Cop 1 (12, 13) . The role of BP in disease induction in the EAE system is well established, and BP is also implicated as a candidate autoantigen in the pathogenesis of MS (3). In EAE, there is usually one major encephalitogenic epitope that is recognized by BP-sensitized cells, expressing species and strain specificity (1). In MS, several laboratories demonstrated responses to multiple epitopes of BP (28) (29) (30) (31) , although T cells from different MS patients were also shown to interact preferentially with the distinct BP epitope, p84-102 (32) . These immunodominant peptides of BP were previously shown to bind to purified MHC class II molecules of both murine and human origin (33, 34) . We have now observed the binding of p84-102 to MHC molecules on living APCs by using a biotinylated analogue. The results show that this peptide bound to human cells of all the DR haplotypes tested, whereas in the murine system binding was to the I-AS but not to the I-Ad haplotype. The DR specificity of p84-102 binding has been shown using purified DR molecules (34) , and similar allele-specific binding to murine I-A molecules was demonstrated for its smaller segment, namely, residues 89-101 (35) .
In multiple DR alleles) has been described using endogenous and exogenously added peptides (39) (40) (41) (42) . A tentative DR motif was recently proposed to consist of an aromatic or hydrophobic residue in position 1, followed by Ser, Thr, Ala, Val, Ile, Leu, Pro, or Cys in position 6 and by a hydrophobic residue in position 9 (41) . Cop 1, composed of Tyr, Ala, Lys, and Glu, therefore, may contain several such motif(s), providing multiple interaction sites.
Of particular importance is the finding that among the HLA-DR alleles shown to bind Cop 1 are also the DRB1*1501 haplotype (Fig. 1H) , tightly linked to MS susceptibility in Caucasian MS patients (43, 44) , and the DR4 haplotype (Fig.  11) , which has been reported to associate with MS in Sardinian (45) 
